Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer's Blood Test

Quanterix is adjusting its sales approach while targeting a Q4 FDA decision on its Alzheimer's blood test, positioning the company for a potential market entry in neurodegenerative diagnostics.

This Wire brief sits within Fusion42's coverage of Diagnostics. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.